Taken together, our results indicate that simultaneous activation of TLR9 and attenuation of A20 expression in DCs using in vivo deliverable CpG-siRNA conjugate is capable of inducing a strong and specific immune response against an established tumor. The gene discussed is TNFAIP3; the disease is neoplasm.